Masked T‑cell engagers: Cancer immunotherapies for the future?

A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a “masked T-cell engager.” This type of immunotherapy ignites our own immune arsenal to fight cancer.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup